Iron and fibroblast growth factor 23 in X-linked hypophosphatemia

被引:20
|
作者
Imel, Erik A. [1 ,2 ]
Gray, Arnie K. [1 ]
Padgett, Leah R. [1 ]
Econs, Michael J. [1 ]
机构
[1] Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46202 USA
[2] Indiana Univ, Sch Med, Dept Pediat, Indianapolis, IN 46202 USA
基金
美国国家卫生研究院;
关键词
Fibroblast growth factor 23; FGF23; X-linked hypophosphatemia; Iron; Phosphate; FGF23; CONCENTRATIONS; FIBROBLAST-GROWTH-FACTOR-23; METABOLISM; INHIBITION; EXPRESSION; MUTATION; RICKETS; PLASMA; KLOTHO; FGF-23;
D O I
10.1016/j.bone.2013.12.001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Excess fibroblast growth factor 23 (FGF23) causes hypophosphatemia in autosomal dominant hypophosphatemic ricicets (ADHR) and X-linked hypophosphatemia (XLH). Iron status influences C-terminal FGF23 (incorporating fragments plus intact FGF23) in ADHR and healthy subjects, and intact FGF23 in ADHR. We hypothesized that in XLH serum iron would inversely correlate to C-terminal FGF23, but not to intact FGF23, mirroring the relationships in normal controls. Methods: Subjects included 25 untreated outpatients with XLH at a tertiary medical center and 158 healthy adult controls. Serum iron and plasma intact FGF23 and C-terminal FGF23 were measured in stored samples. Results: Intact FGF23 was greater than the control mean in 100% of XLH patients, and >2SD above the control mean in 88%, compared to 71% and 21% respectively for C-terminal FGF23. In XLH, iron correlated negatively to log-C-terminal FGF23 (r = -0.523, p <0.01), with a steeper slope than in controls (p <0.001). Iron was not related to log-intact FGF23 in either group. The log-ratio of intact FGF23 to C-terminal FGF23 was higher in XLH (0.00 +/- 0.44) than controls (-0.28 +/- 0.21, p < 0.01), and correlated positively to serum iron (controls r = 0.276, p < 0.001; XLH r = 0.428, p < 0.05), with a steeper slope in XLH (p < 0.01). Conclusion: Like controls, serum iron in XLH is inversely related to C-terminal FGF23 but not intact FGF23. XLH patients are more likely to have elevated intact FGF23 than C-terminal FGF23. The relationships of iron to FGF23 in XLH suggest that altered regulation of FGF23 cleaving may contribute to maintaining hypophosphatemia around an abnormal set-point. (C) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码:87 / 92
页数:6
相关论文
共 50 条
  • [1] Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia
    Kida, Y
    NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (05): : 505 - 505
  • [2] X-linked hypophosphatemia, fibroblast growth factor 23 signaling, and craniosynostosis
    Grimbly, Chelsey
    Graf, Daniel
    Ward, Leanne M.
    Alexander, R. Todd
    EXPERIMENTAL BIOLOGY AND MEDICINE, 2023, 248 (22) : 2175 - 2182
  • [3] Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia.
    Jonsson, KB
    Zahradnik, R
    Larsson, T
    White, KE
    Sugimoto, T
    Imanishi, Y
    Yamamoto, T
    Hampson, G
    Koshiyama, H
    Ljunggren, Ö
    Oba, K
    Yang, IM
    Miyauchi, A
    Econs, MJ
    Lavigne, J
    Jüppner, H
    NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (17): : 1656 - 1663
  • [4] Dental impact of anti-fibroblast growth factor 23 therapy in X-linked hypophosphatemia
    dos Santos, Elis J. Lira
    Nakajima, Kenta
    Po, Julien
    Hanai, Ayako
    Zhukouskaya, Volha
    Duplan, Martin Biosse
    Linglart, Agnes
    Shimada, Takashi
    Chaussain, Catherine
    Bardet, Claire
    INTERNATIONAL JOURNAL OF ORAL SCIENCE, 2023, 15 (01)
  • [5] Fibroblast growth factor-23: The phosphatonin essential to the pathogenesis of X-linked hypophosphatemia (XLH).
    Yuan, B.
    Takaiwa, M.
    Clemens, T. L.
    Hedge, A.
    Rowe, P. S. N.
    Kumar, R.
    Feng, J. Q.
    Drezner, M. K.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2006, 21 : S11 - S11
  • [6] Dental impact of anti-fibroblast growth factor 23 therapy in X-linked hypophosphatemia
    Elis J.Lira dos Santos
    Kenta Nakajima
    Julien Po
    Ayako Hanai
    Volha Zhukouskaya
    Martin Biosse Duplan
    Agnès Linglart
    Takashi Shimada
    Catherine Chaussain
    Claire Bardet
    International Journal of Oral Science, 2023, (04) : 691 - 700
  • [7] Dental impact of anti-fibroblast growth factor 23 therapy in X-linked hypophosphatemia
    Elis J. Lira dos Santos
    Kenta Nakajima
    Julien Po
    Ayako Hanai
    Volha Zhukouskaya
    Martin Biosse Duplan
    Agnès Linglart
    Takashi Shimada
    Catherine Chaussain
    Claire Bardet
    International Journal of Oral Science, 15
  • [8] Treatment of X-Linked Hypophosphatemia with Calcitriol and Phosphate Increases Circulating Fibroblast Growth Factor 23 Concentrations
    Imel, Erik A.
    DiMeglio, Linda A.
    Hui, Siu L.
    Carpenter, Thomas O.
    Econs, Michael J.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (04): : 1846 - 1850
  • [9] X-linked hypophosphatemia and growth
    Fuente, R.
    Gil-Pena, H.
    Claramunt-Taberner, D.
    Hernandez, O.
    Fernandez-Iglesias, A.
    Alonso-Duran, L.
    Rodriguez-Rubio, E.
    Santos, F.
    REVIEWS IN ENDOCRINE & METABOLIC DISORDERS, 2017, 18 (01): : 107 - 115
  • [10] X-linked hypophosphatemia and growth
    R. Fuente
    H. Gil-Peña
    D. Claramunt-Taberner
    O. Hernández
    A. Fernández-Iglesias
    L. Alonso-Durán
    E. Rodríguez-Rubio
    F. Santos
    Reviews in Endocrine and Metabolic Disorders, 2017, 18 : 107 - 115